A Prospective, Double-Blind, Multicenter, Randomized Trial Comparing Ertapenem 3 Vs ≥5 Days in Community-Acquired Intraabdominal Infection |
| |
Authors: | Antonio Basoli Piero Chirletti Ercole Cirino Nicola G D’Ovidio Giovanni Battista Doglietto Domenico Giglio Stefano M Giulini Alberto Malizia Mario Taffurelli Jelena Petrovic Maurizio Ecari |
| |
Institution: | (1) Department “Paride Stefanini”, University “La Sapienza”, Policlinico Umberto I. Viale del Policlinico, 00161 Rome, Italy;(2) Department of Emergency Surgery, University “ La Sapienza”, Rome, Italy;(3) Department of Emergency Surgery, University of Catania, Catania, Italy;(4) Department of Emergency Surgery, University of Sassari, Sassari, Italy;(5) Department of Surgery, Catholic University of Rome, Rome, Italy;(6) Department of Surgery, S. Giovanni Bosco Hospital, Naples, Italy;(7) Department of Surgery, University of Brescia, Brescia, Italy;(8) Department of Emergency Surgery, University of Bologna, Bologna, Italy;(9) Merck Sharp and Dohme, Rome, Italy |
| |
Abstract: | Severe secondary peritonitis is diagnosed in only 20–30% of all patients, but studies to date have persisted in using a standard
fixed duration of antibiotic therapy. This prospective, double-blind, multicenter, randomized clinical study compared the
clinical and bacteriological efficacy and tolerability of ertapenem (1 g/day) 3 days (group I) vs ≥5 days (group II) in 111
patients with localized peritonitis (appendicitis vs non-appendicitis) of mild to moderate severity, requiring surgical intervention.
In evaluable patients, the clinical response as primary efficacy outcome were assessed at the test-of-cure 2 and 4 weeks
after discontinuation of antibacterial therapy. Ninety patients were evaluable. In groups I and II, 92.9 and 89.6% of patients
were cured, respectively; 95.3% in group I and 93.7% in group II showed eradication. These differences were not statistically
significant. The most frequent bacteria recovered were Escherichia coli and Bacteroides fragilis. A wound infection developed in seven patients (7.7%) and an intraabdominal infection in one patient (1.1%). There was a
low frequency of drug-related clinical or laboratory adverse effects in both groups. Our study demonstrated that, in patients
with localized community-acquired intraabdominal infection, a 3-day course of ertapenem had the same clinical and bacteriological
efficacy as a standard duration.
Italian study group: Paolo Mazzocchi, Luigi Solinas, and Fulvio D’Ostuni, Department “Paride Stefanini”, University “La Sapienza”,
Rome, Italy; Roberto Caronna, Department of Emergency Surgery, University “ La Sapienza”, Rome, Italy; Antonino Buffone, Department
of Emergency Surgery, University of Catania, Catania, Italy; Teresa Verde and Claudia Massaiu, Department of Emergency Surgery,
University of Sassari, Sassari, Italy; Dario Di Miceli, Department of Surgery, Catholic University of Rome, Rome, Italy; Salvatore
Di Muria, Department of Surgery, S. Giovanni Bosco Hospital, Naples, Italy; Edoardo Cervi, Department of Surgery, University
of Brescia, Brescia, Italy; Fausto Catena, Department of Emergency Surgery, University of Bologna, Bologna, Italy; Massimo
Coletti and Stefano Scozzafava, Department of Emergency Surgery, University “La Sapienza”, Rome, Italy
This paper was presented at the 20th meeting of the International Society for Digestive Surgery, Rome, Italy, November 29–December1,
2006. |
| |
Keywords: | Peritonitis Ertapenem Localized intraabdominal infection Surgical and antibiotic therapy |
本文献已被 SpringerLink 等数据库收录! |
|